----item----
version: 1
id: {A1988028-6120-41B3-BB63-86641FC3309E}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/02/27/GSK execs take financial and medical reins at Adaptimmune
parent: {8E71AD2E-3D59-4E74-B732-B3CC0A62D38F}
name: GSK execs take financial and medical reins at Adaptimmune
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 620b4f9f-3fa3-461d-83ce-fd3b7a345a61

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{728904A1-7259-48E8-8256-60D002A0BFEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 57

GSK execs take financial and medical reins at Adaptimmune
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 57

GSK execs take financial and medical reins at Adaptimmune
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1307

<p>Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, has named Dr Rafael Amado chief medical officer and Adrian Rawcliffe chief financial officer &ndash; effective from 16 March 2015.</p><p>Dr Amado will lead Adaptimmune's clinical strategy and assume responsibility for the company's clinical trials across the US and Europe under its strategic collaboration with GlaxoSmithKline. Prior to joining Adaptimmune, Dr Amado was senior vice-president and head of oncology R&D at GSK. </p><p>Mr Rawcliffe also joins the company from GSK where he was senior vice-president of finance for the big pharma's North American business. </p><p>In June 2014 Adaptimmune entered into a collaboration and licensing agreement with GlaxoSmithKline worth up to $350m, for the development and commercialization of its NY-ESO TCR program (<a href="http://www.scripintelligence.com/business/350m-Adaptimmune-deal-shows-GSK-still-does-cancer-RandD-352090" target="_new">scripintelligence.com, 2 June 2014</a>). And in September, the company completed a $104m series A financing round (<a href="http://www.scripintelligence.com/home/UK-biotech-Adaptimmune-raises-104m-series-A-to-build-US-style-company-354114" target="_new">scripintelligence.com, 25 September 2014</a>).</p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 243

<p>Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, has named Dr Rafael Amado chief medical officer and Adrian Rawcliffe chief financial officer &ndash; effective from 16 March 2015.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 57

GSK execs take financial and medical reins at Adaptimmune
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150227T120000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150227T120000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150227T120000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC027995
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 57

GSK execs take financial and medical reins at Adaptimmune
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

198800586
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356978
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042303Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

620b4f9f-3fa3-461d-83ce-fd3b7a345a61
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042303Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
